STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
An analysis suggests that Trump's secretive pharmaceutical deals could significantly diminish the projected savings from his administration's plan to reduce Medicare drug costs, potentially by as much as 80%. This approach, known as "most-favored nation" pricing, aims to align Medicare's drug prices with those paid by 19 other wealthy nations.
The White House claims this initiative would save Medicare $26 billion over several years and help address the issue of prescription drugs becoming increasingly unaffordable. To achieve this goal, the administration is implementing two pilot programs - GLOBE for Medicare Part B and GUARD for Medicare Part D. These programs require drug companies to pay additional rebates if their prices surpass the lowest international price found in the selected 19 countries. More precise details regarding the rules are expected to be released soon.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
